 |
|
|
| |
INTERFERON-FREE TREATMENT WITH FALDAPREVIR, DELEOBUVIR, AND RIBAVIRIN IN SOUND-C3: 95% SVR12 IN HCV GENOTYPE-1b
|
| |
| |
Reported by Jules Levin
AASLD Nov 1-4 2013 Wash DC
JF Dufour1, M Buti2, V Soriano3, R Buynak4, P Mantry5, J Taunk6, JO Stern7, R Vinisko7, JP Gallivan8, WO Bocher8, FJ Mensa7, S Zeuzem9, on behalf of the SOUND-C3 Study Group1University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 2Hospital Vall d'Hebron, Barcelona, Spain; 3Hospital Carlos III, Madrid, Spain; 4Northwest Indiana Center for Clinical Research, Valparaiso, IN, USA; 5The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA; 6Advance Gastroenterology Associates, LLC, Palm Harbor, FL, USA; 7Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 8Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany, 9J.W. Goethe University Hospital, Frankfurt, Germany
AASLD: Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection - (11/04/13)
|
| |
|
|
|
|
|
